| 801 |
Cord Tissue |
Allogeneic – Unrelated |
Autism |
Neurology |
2025 |
Experimental Therapy |
Poland |
15,2 |
| 802 |
Cord Tissue |
Allogeneic – Unrelated |
GvHD |
Immunology |
2025 |
Experimental Therapy |
Poland |
13 |
| 803 |
Cord Tissue |
Allogeneic – Unrelated |
Cartilage Lesions |
Orthopedics |
2025 |
Experimental Therapy |
Poland |
48,2 |
| 804 |
Cord Tissue |
Allogeneic – Unrelated |
Cartilage Lesions |
Orthopedics |
2025 |
Experimental Therapy |
Poland |
51,6 |
| 805 |
Cord Tissue |
Allogeneic – Unrelated |
GvHD |
Hematology |
2025 |
Experimental Therapy |
Poland |
12,9 |
| 806 |
Cord Tissue |
Allogeneic – Unrelated |
Autism |
Neurology |
2025 |
Experimental Therapy |
Poland |
10,1 |
| 807 |
Cord Tissue |
Allogeneic – Unrelated |
Autism |
Neurology |
2025 |
Experimental Therapy |
Poland |
8,4 |
| 808 |
Cord Tissue |
Allogeneic – Unrelated |
Cerebral Palsy |
Neurology |
2025 |
Experimental Therapy |
Poland |
3,7 |
| 809 |
Cord Tissue |
Allogeneic – Unrelated |
Cerebral Infarction |
Neurology |
2025 |
Experimental Therapy |
Poland |
57,8 |
| 810 |
Cord Tissue |
Allogeneic – Unrelated |
Autism |
Neurology |
2025 |
Experimental Therapy |
Poland |
7,7 |
| 811 |
Cord Tissue |
Allogeneic – Unrelated |
Cerebellar Syndrome |
Neurology |
2025 |
Experimental Therapy |
Poland |
43,4 |
| 812 |
Cord Tissue |
Allogeneic – Unrelated |
Cartilage Lesions |
Orthopedics |
2025 |
Experimental Therapy |
Poland |
61,1 |
| 813 |
Cord Tissue |
Allogeneic – Unrelated |
Cartilage Lesions |
Orthopedics |
2025 |
Experimental Therapy |
Poland |
57,9 |
| 814 |
Cord Tissue |
Allogeneic – Unrelated |
Cerebral Palsy |
Neurology |
2025 |
Experimental Therapy |
Poland |
1,2 |
| 815 |
Cord Tissue |
Allogeneic – Unrelated |
Cerebral Palsy |
Neurology |
2025 |
Experimental Therapy |
Poland |
7,1 |
| 816 |
Cord Tissue |
Allogeneic – Unrelated |
Autism |
Neurology |
2025 |
Experimental Therapy |
Poland |
3 |
| 817 |
Cord Blood |
Allogeneic – Related |
Thalassemia Major |
Hematology |
2025 |
Standard Therapy |
Turkey |
5,9 |
| 818 |
Cord Blood |
Autologous |
Aplastic Anemia |
Hematology |
2025 |
Standard Therapy |
Poland |
2 |
| 819 |
Cord Blood |
Allogeneic – Related |
Thalassemia Major |
Hematology |
2025 |
Standard Therapy |
Turkey |
6,8 |
| 820 |
Cord Blood |
Allogeneic – Related |
Cerebral Palsy |
Neurology |
2025 |
Experimental Therapy |
Portugal |
1 year and 8 months |
| 821 |
Cord Blood |
Autologous |
Autism |
Neurology |
2025 |
Experimental Therapy |
Romania |
5 |
| 822 |
Cord Blood |
Allogeneic |
Acute lymphoblastic leukemia |
Hematology |
2025 |
Standard Therapy |
Poland |
13 |
| 823 |
Cord Blood |
Autologous |
Autism |
Neurology |
2025 |
Experimental Therapy |
Poland |
5 ,5 |
| 824 |
Cord Blood |
Autologous |
Autism |
Neurology |
2025 |
Experimental Therapy |
Poland |
7,2 |
| 825 |
Cord Blood |
Allogeneic |
Thalassemia Major |
Hematology |
2025 |
Standard Therapy |
Turkey |
10,9 |
| 826 |
Cord Blood |
Autologous |
Autism |
Neurology |
2025 |
Experimental Therapy |
Poland |
4,1 |
| 827 |
Cord Blood |
Autologous |
Cerebral Palsy |
Neurology |
2025 |
Experimental Therapy |
Poland |
3,1 |
| 828 |
Cord Blood |
Autologous |
Autism |
Neurology |
2025 |
Experimental Therapy |
Poland |
5,2 |
| 829 |
Cord Blood |
Autologous |
Autism |
Neurology |
2025 |
Experimental Therapy |
Poland |
2,11 |
| 830 |
Cord Blood |
Autologous |
Unbalanced AVSD |
Cardiovascular |
2025 |
Experimental Therapy |
Poland |
5 months |
| 831 |
Cord Blood |
Allogeneic – Related |
Relapsed Lymphoblastic Leukemia |
Hematology |
2025 |
Standard Therapy |
Turkey |
8,5 |
| 832 |
Cord Blood |
Autologous |
Autism |
Neurology |
2025 |
Experimental Therapy |
Poland |
10,1 |
| 833 |
Cord Blood |
Autologous |
Autism |
Neurology |
2025 |
Experimental Therapy |
Poland |
5,7 |
| 834 |
Cord Blood |
Autologous |
Autism |
Neurology |
2025 |
Experimental Therapy |
Poland |
4,4 |
| 835 |
Cord Blood |
Autologous |
Autism |
Neurology |
2025 |
Experimental Therapy |
Poland |
5,5 |
| 836 |
Cord Blood |
Autologous |
Autism |
Neurology |
2025 |
Experimental Therapy |
Poland |
5,4 |
| 837 |
Cord Blood |
Autologous |
Autism |
Neurology |
2025 |
Experimental Therapy |
Poland |
3,9 |
| 838 |
Cord Blood |
Allogeneic – Related |
D57.1 Sickle Cell Anemia |
Hematology |
2025 |
Standard Therapy |
Turkey |
5 years 6 months |
| 839 |
Bone Marrow Family |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
France |
66 |
| 840 |
Bone Marrow Family |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
Germany |
63 |
| 841 |
Bone Marrow Family |
Allogeneic |
Myelofibrosis |
Hematology |
2025 |
Standard Therapy |
Poland |
71 |
| 842 |
Bone Marrow Family |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
United Kingdom |
72 |
| 843 |
Bone Marrow Family |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
France |
47 |
| 844 |
Bone Marrow Family |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2025 |
Standard Therapy |
Ukraine |
43 |
| 845 |
Bone Marrow Family |
Allogeneic |
Acute Lymphoblastic Leukemia |
Hematology |
2025 |
Standard Therapy |
Italy |
49 |
| 846 |
Bone Marrow Family |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
France |
51 |
| 847 |
Bone Marrow Family |
Allogeneic |
Philadelphia – positive Acute Lymphoblastic Leukemia |
Hematology |
2025 |
Standard Therapy |
Germany |
61 |
| 848 |
Bone Marrow Family |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
France |
58 |
| 849 |
Bone Marrow Family |
Allogeneic |
Myelofibrosis |
Hematology |
2025 |
Standard Therapy |
NETHERLANDS |
63 |
| 850 |
Bone Marrow Family |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
Poland |
65 |
| 851 |
Bone Marrow Family |
Allogeneic |
Acute Lymphoblastic Leukemia |
Hematology |
2025 |
Standard Therapy |
France |
63 |
| 852 |
Bone Marrow Family |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2025 |
Standard Therapy |
Poland |
68 |
| 853 |
Bone Marrow Family |
Allogeneic |
Myelofibrosis |
Hematology |
2025 |
Standard Therapy |
France |
71 |
| 854 |
Bone Marrow Family |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
Russia |
51 |
| 855 |
Bone Marrow Family |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
Germany |
62 |
| 856 |
Bone Marrow Family |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
Czechia |
54 |
| 857 |
Bone Marrow Family |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
United Kingdom |
16 |
| 858 |
Bone Marrow Family |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
USA |
61 |
| 859 |
Bone Marrow Family |
Allogeneic |
Chronic Myelomonocytic Leukemia |
Hematology |
2025 |
Standard Therapy |
Poland |
61 |
| 860 |
Bone Marrow Family |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
Italy |
70 |
| 861 |
Bone Marrow Family |
Allogeneic |
PostET Myelofibrosis |
Hematology |
2025 |
Standard Therapy |
Netherlands |
21 |
| 862 |
Bone Marrow Family |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
Poland |
68 |
| 863 |
Bone Marrow Family |
Allogeneic |
Acute Myelogenous Leukemia/ Mielodysplastic Syndrome |
Hematology |
2025 |
Standard Therapy |
Germany |
65 |
| 864 |
Bone Marrow Family |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
NETHERLANDS |
60 |
| 865 |
Bone Marrow Family |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2025 |
Standard Therapy |
USA |
33 |
| 866 |
Bone Marrow Family |
Allogeneic |
Muscular Dystrophy Association |
Hematology |
2025 |
Standard Therapy |
United Kingdom |
75 |
| 867 |
Bone Marrow Family |
Allogeneic |
Acute Myeloid Leukemia |
Hematology |
2025 |
Standard Therapy |
Germany |
72 |
| 868 |
Bone Marrow Family |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
USA |
77 |
| 869 |
Bone Marrow Family |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
France |
23 |
| 870 |
Bone Marrow Family |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2025 |
Standard Therapy |
Germany |
58 |
| 871 |
Bone Marrow Family |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
United Kingdom |
53 |
| 872 |
Bone Marrow Family |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2025 |
Standard Therapy |
Germany |
75 |
| 873 |
Bone Marrow Family |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
Germany |
61 |
| 874 |
Bone Marrow Family |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
France |
8 |
| 875 |
Bone Marrow Family |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
Germany |
63 |
| 876 |
Bone Marrow Family |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
Ukraine |
38 |
| 877 |
Bone Marrow Family |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2025 |
Standard Therapy |
Germany |
70 |
| 878 |
Bone Marrow Family |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2025 |
Standard Therapy |
USA |
69 |
| 879 |
Bone Marrow Family |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
France |
31 |
| 880 |
Bone Marrow Family |
Allogeneic |
Acute Myleogenous Leukemia, alloPBST 7/2025 |
Hematology |
2025 |
Standard Therapy |
Germany |
53 |
| 881 |
Bone Marrow |
Allogeneic |
Aplastic Anemia |
Hematology |
2025 |
Standard Therapy |
Spain |
15 |
| 882 |
Bone Marrow |
Allogeneic |
Severe Aplastic Anemia |
Hematology |
2025 |
Standard Therapy |
Norway |
55 |
| 883 |
Bone Marrow |
Allogeneic |
Inherited Immune System Disorder |
Hematology |
2025 |
Standard Therapy |
France |
3 |
| 884 |
Bone Marrow |
Allogeneic |
Acute Lymphoblastic Leukemia |
Hematology |
2025 |
Standard Therapy |
USA |
7 |
| 885 |
Bone Marrow |
Allogeneic |
Severe Aplastic Anemia |
Hematology |
2025 |
Standard Therapy |
Ukraine |
36 |
| 886 |
Bone Marrow |
Allogeneic |
Inherited Immune System Disorder |
Hematology |
2025 |
Standard Therapy |
France |
10 |
| 887 |
Bone Marrow |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2025 |
Standard Therapy |
USA |
76 |
| 888 |
Bone Marrow |
Allogeneic |
Severe Aplastic Anemia |
Hematology |
2025 |
Standard Therapy |
Poland |
39 |
| 889 |
Bone Marrow |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
South Africa |
6 |
| 890 |
Bone Marrow |
Allogeneic |
Wiskott-Aldrich syndrome |
Hematology |
2025 |
Standard Therapy |
Turkey |
6 |
| 891 |
Bone Marrow |
Allogeneic |
Combined immnunodeficiency |
Hematology |
2025 |
Standard Therapy |
Ukraine |
3 months |
| 892 |
Bone Marrow |
Allogeneic |
Chronic Granulomatous Disease |
Hematology |
2025 |
Standard Therapy |
Poland |
3 |
| 893 |
Bone Marrow |
Allogeneic |
Mixed Phenotype Acute Leukemia |
Hematology |
2025 |
Standard Therapy |
Poland |
13 |
| 894 |
Bone Marrow |
Allogeneic |
Severe Aplastic Anemia |
Hematology |
2025 |
Standard Therapy |
Poland |
7 |
| 895 |
Bone Marrow |
Allogeneic |
B-cell precursor Acute Lymphoblastic Leukemia |
Hematology |
2025 |
Standard Therapy |
Poland |
56 |
| 896 |
Bone Marrow |
Allogeneic |
Severe Aplastic Anemia |
Hematology |
2025 |
Standard Therapy |
Poland |
43 |
| 897 |
Bone Marrow |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2025 |
Standard Therapy |
Poland |
19 |
| 898 |
Bone Marrow |
Allogeneic |
Very Severe Aplastic Anemia |
Hematology |
2025 |
Standard Therapy |
Poland |
12 |
| 899 |
Bone Marrow |
Allogeneic |
Acute Lymphoblastic Leukemia |
Hematology |
2025 |
Standard Therapy |
Poland |
5 |
| 900 |
Bone Marrow |
Allogeneic |
Acute Lymphoblastic Leukemia |
Hematology |
2025 |
Standard Therapy |
Poland |
10 months |